Xeris Biopharma Holdings Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Xeris Biopharma Holdings, Inc. (XERS) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-54.84-36.68-94.66-122.73-91.14
Depreciation & Amortization12.636.8412.671.881.47
Deferred Income Tax-2.27-1.25-1.420.000.00
Stock Based Compensation18.3610.7212.1611.388.27
Change in Working Capital-8.82-13.02-35.1511.85-2.80
Change in Accounts Receivable-1.22-8.37-13.37-6.24-2.18
Change in Inventory-8.78-14.80-7.47-7.42-5.14
Change in Accounts Payable-9.616.96-4.325.53-2.49
Change in Other Working Capital-1.389.92-9.9919.987.01
Other Operating Activities-1.382.970.110.702.58
Net Cash from Operating Activities-36.98-39.88-102.89-95.54-80.56
Investing Activities
Capital Expenditures-0.871.79-0.52-1.09-0.38
Acquisitions0.000.000.0038.470.00
Purchases of Investments-34.49-3.7434.9960.58-27.03
Sales/Maturities of Investments40.24-33.7434.99103.600.00
Net Cash from Investing Activities4.88-35.5334.4697.96-27.41
Financing Activities
Debt Repayment-11.830.00-44.230.000.00
Common Stock Issued1.730.5530.8427.8466.70
Common Stock Repurchased-3.73-1.01-0.47-0.53-0.06
Other Financing Activities-11.83-0.89-5.61-0.05-10.32
Net Cash from Financing Activities36.17-0.31127.4727.25126.06
Summary
Effect of Forex Changes on Cash0.000.000.000.000.00
Net Change in Cash4.07-75.7259.0429.6718.08
Cash at Beginning of Period71.67126.3167.2737.600.00
Cash at End of Period75.7450.60126.3167.270.00
Free Cash Flow-37.85-41.67-103.42-96.62-80.94
Supplemental Disclosures
Interest Paid26.9527.6910.867.294.56